Lacidipine is a third-generation dihydropyridine calcium channel blocker that has a demonstrated effectiveness against hypertension. It has been shown to have a preventative effect on myocardial hypertrophy and remodeling in male spontaneously hypertensive rats. In patient-derived Gaucher’s disease fibroblasts, lacidipine has been found to enhance folding, trafficking, and activity of mutated glucocerebrosidase variants. It has been observed to function as a proteostasis regulator and to rescue L444P GC folding with considerably high efficiency by upregulating BiP expression. In addition to blocking L-type Ca2+ channels on the plasma membrane, it has been found to block Ryanodine receptors on the endoplasmic reticulum membrane. It has been shown to activate each of the three arms of the unfolded protein response signal transduction cascade and yet to prevent apoptosis induction, thereby promoting cell survival. Furthermore, lacidipine has been shown to possess antibacterial activity against various organisms, including Vibrio cholerae 569B cells in experimental rabbit ileal loops.